News

Intrinsic Therapeutics Achieves Milestone with CPT Code Approval

Intrinsic Therapeutics Achieves Milestone with CPT Code Approval

Intrinsic Therapeutics Secures New CPT Code for Barricaid

Intrinsic Therapeutics, Inc. has recently announced a significant advancement in the field of spinal surgery with the approval of a new Category 1 CPT Code. This code is specifically for bone anchored annular closure, and it includes the Barricaid® Annular Closure Device, which is instrumental for patients undergoing lumbar discectomy aimed at treating herniated discs.

The Importance of CPT Code Approval

The approval of a new Category 1 CPT code is a commendable achievement that underscores the potential of innovative medical technologies. According to reports, the American Medical Association (AMA) CPT Editorial Panel has accepted this code, which is a breakthrough for procedures that utilize the Barricaid device. This device is designed to close large annular defects and is routinely used by orthopaedic spine and neurosurgeons across various healthcare facilities.

Significant Milestone for Barricaid

Dr. Serena Hu, Chief of Orthopaedic Spine Service, emphasized the importance of this new CPT code, stating that it indicates high levels of clinical evidence and efficacy. The categorization not only reflects the rigorous criteria set by the AMA but also signifies the widespread acceptance of Barricaid as a valid therapeutic alternative. Additionally, the accomplishment of securing this code provides a structured pathway for reimbursement, which is vital for healthcare providers.

Key Milestones Achieved

This recent achievement aligns with a series of important milestones for Barricaid over the years. Key achievements include statistical superiority over discectomy alone, FDA Premarket Approval (PMA), and the issuance of a clinical C-Code by the Center for Medicare & Medicaid Services (CMS) for facility payments. Furthermore, ICD-10-CM codes from the Centers for Disease Control and Prevention (CDC) now enable the reporting of large annular defects, which reinforces Barricaid's role in clinical practice.

Collaborative Efforts Behind the Success

Ryan Drant, Chairman of the Board at Intrinsic Therapeutics, expressed gratitude for the collaborative effort of healthcare organizations such as the FDA, CDC, and AMA. These collaborations have been essential in gathering clinical evidence that paves the way for such approvals. The teamwork between surgeons and specialty medical societies has played a significant role in achieving these milestones that ultimately benefit patient care.

About Barricaid Technology

Barricaid is a proprietary technology that has been developed to prevent reherniation and reduce the need for reoperation in patients with large annular defects following lumbar discectomy surgery. It has been successfully implanted in over eleven thousand patients. Barricaid is supported by a wealth of clinical studies spanning eight different patient populations, including two randomized controlled trials and six single-armed trials. A notable multicenter level I randomized controlled trial showcased its superior outcomes in comparison to discectomy alone, further solidifying its place in therapeutic practices.

Frequently Asked Questions

What is the significance of the new CPT code for Barricaid?

The new Category 1 CPT code is essential as it indicates that Barricaid meets stringent clinical evidence requirements and is a reliable option for treating patients with herniated discs.

How does Barricaid work?

Barricaid functions by anchoring the annulus of the disc to prevent reherniation and enhance recovery for patients undergoing lumbar discectomy.

What are the benefits of the CPT code for doctors?

For physicians, the CPT code provides clarity in reimbursement processes and enhances the standard of care for patients, indicating broader acceptance in surgical practices.

How many patients have received the Barricaid implant?

More than eleven thousand patients have been implanted with the Barricaid device, showcasing its extensive usage and clinical validation.

What is the future of Barricaid with the new CPT code?

The new CPT code will play a crucial role in streamlining reimbursement processes, potentially increasing utilization and enhancing patient access to this innovative technology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 30

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 33

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 232

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 65

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 124

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 9

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading

Top 5 Most Recently Viewed Articles

Ping An Healthcare Delivers Impressive Growth in Interim Results

Updated Category News Views 186

Impressive Interim Results from Ping An Healthcare Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) has announced robust interim results for the six-month period ending June 30, showing significant progress following its return to profitability. Throughout this period, the Company has demonstrated strong revenue growth and a notable...

Continue Reading
Market Insights: Trends in Precious Metals and Sector Performance

Updated Category News Views 201

Understanding Market Dynamics and Precious Metals The current landscape of Wall Street might appear quiet at first glance, especially during the lull between holidays. However, beneath this surface lies a surge of activity, particularly in the realm of precious metals. Investors are keenly observing the uptick in volatility, specifically concerning silver and other key...

Continue Reading
Discover the Most Popular Pet Breeds of 2025: Insights and Trends

Updated Category News Views 409

Understanding the 2025 Top Pet Breeds The bond between pets and their owners often mirrors our own personalities and values. Recent insights reveal that 8 out of 10 pet parents believe a dog breed reflects a person's character. Across different breeds, qualities such as friendliness, sociability, and playfulness top the charts when pet parents make their choices. The...

Continue Reading
Amicus Therapeutics Engages Investors at Key Conferences Soon

Updated Category News Views 129

Amicus Therapeutics to Present at Upcoming Investor Conferences Amicus Therapeutics (Nasdaq: FOLD), a dedicated player in the biotechnology landscape, has announced its forthcoming participation in significant investor conferences this September, showcasing its unwavering commitment to fostering investor relations. Details of the Upcoming Presentations The company has...

Continue Reading
Understanding RPM Intl's P/E Ratio in Market Context

Updated Category News Views 206

Understanding RPM Intl's Stock Performance Currently, RPM Intl Inc. (NYSE: RPM) is experiencing a share price of $123.50, reflecting a modest increase of 0.36%. This uptick is notable amidst a turbulent month, where the stock has decreased by 11.21%. However, when we look back over the past year, we see a positive trend, with the stock appreciating by 16.26%. Investors...

Continue Reading